37 results about "Enolase" patented technology

The invention discloses a construction method and application of an ultra-sensitive self-enhanced electrochemical luminescence biosensor, and belongs to the technical fields of biochemical analysis, nano materials and life science. According to the preparation method disclosed by the invention, Cu < 2 + > is introduced into luminous ZrEu-MOF, and a co-reactant K2S2O8 is catalyzed by the Cu < 2 + > to generate more active free radicals, so that ZrEuCu-MOF with a self-enhancement function is prepared; resorcinol-formaldehyde resin with an egg yolk structure is further synthesized as a quenching probe, and effective quenching of a light-emitting signal is realized based on electrochemical luminescence (ECL) resonance energy transfer between the resorcinol-formaldehyde resin and ZrEuCu-MOF, so that the detection sensitivity is improved. The constructed ECL biosensor realizes efficient and sensitive detection of neuron-specific enolase, and has the advantages of low detection limit, wide detection range, good stability and industrial application prospect.

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention discloses a chimeric antigen receptor targeting human alpha-enolase, a CAR-T cell and application of the chimeric antigen receptor. The invention relates to a chimeric antigen receptor targeting human alpha-enolase, the chimeric antigen receptor comprises an scFv structural domain aiming at the human alpha-enolase, a transmembrane region and an intracellular signal transduction region, and the amino acid sequence of the chimeric antigen receptor is SEQUENCE No.1. The chimeric antigen receptor aiming at the tumor metabolic protein ENO1 is constructed, on one hand, tumor cells are recognized and killed through the highly expressed ENO1, and on the other hand, the chimeric antigen receptor has the effect of inhibiting invasion and metastasis of the tumor cells. Compared with ENO1 monoclonal antibody targeted therapy, the ENO1CAR therapy can directly kill tumor cells, and the effect is stronger; compared with other CAR treatment targets, the ENO1 has more adaptations and can play a role in inhibiting invasion and metastasis of tumors.

Provided is the use of an effective amount of alpha-enolase (enolase-1, ENO-1) antagonist in manufacturing a medicament for treating a fibrotic disease. ENO-1 antagonist significantly attenuated body weight loss and lung weight gain as well as the fibrosis lesion and collagen deposition in lungs. Also, ENO-1 antagonist significantly reduced cell migration and secretion of collagen and TGF-β in primary mouse lung myofibroblasts.

The invention belongs to the technical field of bioinformatics and medical detection, and particularly relates to a marker combination for neuroblastoma (NB) noninvasive risk level grading, a prediction model, a prediction method and application thereof. The marker combination is used for determining the sex, determining whether the month age is greater than 18 months, determining whether plasma MYCN is amplified, determining whether tumors are metastatic, and determining the content of neuron-specific enolase and lactic dehydrogenase; a machine learning algorithm is used for constructing an NB noninvasive risk degree grading prediction model, the comprehensive performance of the random forest model is optimal, the area value under a subject working characteristic curve reaches 0.956, the sensitivity is 92.9%, the specificity is 82.1%, the accuracy rate is 87.5%, the Kappa value is 0.75, the F1 score is 0.881, and NB middle and low risk patients and NB high risk patients can be effectively distinguished; the NB non-invasive risk level grading prediction model constructed by the invention can quickly, accurately and non-invasively perform NB risk level grading, and has a relatively good clinical application value.

The invention relates to the technical field of genetic engineering, and discloses an engineering bacterium for high yield of D-pantothenic acid based on balanced sugar utilization, and a construction method and application thereof. Firstly, pfkB, eno and pgi genes of a glycolysis EMP pathway are weakened, zwf and pgl genes are overexpressed at the same time, and part of carbon flow flows into a PPP pathway in a push-pull mode; secondly, 6-phosphofructokinase II PfkB is knocked out, an initiation codon of an enolase gene eno is modified, and the enzyme activity of glucose phosphate isomerase Pgi is weakened; then, in order to enable the carbon flow to further flow to the PPP and ED paths, overexpressing common genes zwf and pgl of the PPP and ED, introducing edd and eda genes derived from zymomonas mobilis, and getting through the ED path in escherichia coli; thirdly, distributing redundant carbon flow of a PPP path to TCA circulation, and integrating an fxpk gene derived from bifidobacterium adolescentis and a pta gene derived from clostridium kruivmensis in a genome; and finally, through the combined action, the titer of the D-pantothenic acid reaches 4.80 g / L.

Provided herein are methods for treating an angiogenesis-related disease comprising administration to a subject in need thereof an effective amount of alpha-enolase (enolase-1. ENO-1) antagonist.

The invention provides a GFAP recombinant protein, a monoclonal antibody and a preparation method and application thereof. The invention realizes efficient, soluble and active expression of GFAP in Escherichia coli by optimizing antigen peptide sequences and expression vectors. Mouse monoclonal antibodies specifically binding to GFAP protein are screened based on the GFAP recombinant protein, and paired monoclonal antibodies are screened using the mouse monoclonal antibodies. An ELISA detection method or kit for double antibody sandwich immunization and biotin-anti-biotin monoclonal antibody amplification applied to GFAP is further constructed based on the monoclonal antibody combination. The method or kit can specifically detect human GFAP protein, has no cross reaction with other neural markers S-100B protein and neuron-specific enolase (NSE), is consistent with the detection value of a fixed-value calibrator, and has high detection sensitivity.

The present invention relates to the field of artificial polynucleotides and in particular to RNA polynucleotides comprising specific 5'UTR – 3'UTR gene combinations. Provided herein is an RNA polynucleotide comprising at least one 5'UTR element selected from a gene such as ANXA1, E. Coli enolase, RPS14, RPS25, or TCV and at least one 3'UTR selected from a gene such as HBA1, RPS29, Ube2d2a, or UBL5. The invention further relates to a pharmaceutical composition comprising one or more RNA polynucleotides according to the invention and a method of inducing an enhanced immune response in a subject using said RNA polynucleotides or pharmaceutical composition.

This application discloses a method for determining the standard value of neuron-specific enolase (NSE) solution, belonging to the field of biotechnology. The determination method provided in this application includes characterizing the physicochemical properties of the NSE standard candidate solution, such as purity, molecular weight, secondary structure, and bioactivity; diluting and dispensing the NSE standard candidate solution; accurately determining the content of the NSE standard candidate solution and verifying its homogeneity and stability using isotope dilution mass spectrometry based on amino acid analysis and characteristic peptide analysis; and evaluating the uncertainty of the NSE solution standard value determination results. The determination method provided in this application has good reliability and accuracy, and the determination results are traceable to SI units (mol).

The invention discloses deoxyribozyme targeting enolase 1 and application of deoxyribozyme in preparation of a gene medicine for treating rheumatoid arthritis, and belongs to the technical field of biology. On the basis of a mouse ENO1 mRNA secondary structure, 15 deoxyribozyme is designed and screened, Dz8 has the strongest ENO1 mRNA cutting capacity, and the expression level of the gene can be effectively reduced; meanwhile, the Dz8 has Mg-dependent efficient ENO1 mRNA cleavage activity and time-dependent multi-turnover kinetic characteristics, ENO1 expression can be remarkably inhibited at the gene and protein levels, then inflammatory factor secretion is reduced, the glycolysis level is regulated and controlled, and the Dz8 has important application prospects in the field of rheumatoid arthritis gene therapy. The invention provides a new target and a treatment strategy for rheumatoid arthritis gene therapy, and Dz8 is expected to become a potential tool for rheumatoid arthritis gene therapy.

The present invention provides methods and uses for treating or preventing fibrosis and fibrotic diseases, including administering a composition containing an enolase inhibitor such as POMHEX.

Provided are identifies new methods for regulating (or reprogramming) glycolytic reaction by using alpha-enolase (ENO-1) antagonist or agonist. More specifically, provided are methods for glycolysis reprogramming by targeting extracellular ENO-1 or membrane-associated ENO-1.

The invention relates to application of pyruvate kinase (PKM), triosephosphate isomerase (TPI1), alpha-enolase (ENO1) and lactic dehydrogenase (LDHB) in urine in preparation of medicines for exercise function evaluation (exercise intensity, exercise density, exercise duration, exercise function, exercise posture and physiological state), exercise risk prediction, exerciser physique evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise and scientific exercise guidance, exercise scheme screening and other reagents are applied. Research proves that the proteins PKM, TPI1, ENO1 and LDHB in urine are key proteins for exercise training monitoring for the first time. Compared with the prior art, the expression of the four proteins in a urine sample after movement is obviously increased. The sensitivity and the specificity of various purposes such as function evaluation, exercise risk prediction and scientific exercise guidance of exercise training can be improved through independent use of one of the components and combined use of multiple components.

The invention discloses an application of enolase 1 (ENO1) as RNA (Ribonucleic Acid) binding protein in myoblast differentiation. Specifically, the invention discloses application of ENO1 protein as a negative regulatory factor in regulating myoblast differentiation. Different types of ENO1 inhibitors are developed, including siRNA, shRNA and sgRNA for silencing or knocking out ENO1 genes, and the different types of inhibitors can remarkably promote differentiation and fusion of myoblasts. Results prove that the ENO1 as an RNA binding protein directly regulates the expression of HDAC2, by reducing the expression of ENO1 protein and increasing the expression of HDAC2, the expression of ALT1 and ALT2 is promoted, the metabolic level of alanine is improved, the differentiation and fusion of myoblasts are promoted, and the growth and development of skeletal muscles are further promoted. The method has wide application prospects in the fields of animal husbandry industry muscle variety improvement and the like.

The invention discloses a gastric cancer biomarker ENO3 and a detection reagent thereof, belongs to the technical field of biological medicines, and particularly relates to a detection reagent of a gastric cancer marker. The detection reagent comprises an upstream primer and a downstream primer of a gastric cancer marker, and modified immunomagnetic beads, the gastric cancer marker is enolase 3. The invention finds and verifies that the gastric cancer marker enolase 3 promotes malignant transformation of gastric cancer by promoting glycolysis of gastric cancer cells, activating a WNT / beta-catenin signal channel and up-regulating expression of matrix metalloproteinase at the same time; meanwhile, by optimizing an immunomagnetic bead structure targeting the marker, the capture efficiency of the marker on trace tumor cells in peripheral blood is improved, so that the signal intensity of subsequent marker detection is enhanced, and an important tool is provided for improving the positive detection rate of gastric cancer detection based on the peripheral blood.

The present disclosure relates to methods and materials for the production of resveratrol in yeasts (e.g., yeast of the Saccharomyces genus such as S. cerevisiae) by increasing expression of genes of pentose phosphate or Shikimate pathway and others like acetyl- CoA synthase, transketolase, transaldolase, enolase, aromatic aminotransferase, prephenate dehydratase and ribose-5-phosphate isomerase to increase substrate supply for resveratrol biosynthesis or a monocarboxylate permease to transport product out of cells.

Provided are identifies new methods for regulating (or reprogramming) glycolytic reaction by using alpha-enolase (ENO-1) antagonist or agonist. More specifically, provided are methods for glycolysis reprogramming by targeting extracellular ENO-1 or membrane-associated ENO-1.

Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.

The invention provides a dermatophagoides farinae prevention and control alpha-enolase target gene and a preparation method and application of dermatophagoides farinae prevention and control dsRNA, the dermatophagoides farinae prevention and control alpha-enolase target gene is used as the target gene, a high-quality dust alpha-enolase gene is cloned and expressed, the dsRNA of the gene is prepared, and the dsRNA is used as a biological acaricide for preventing and controlling the dermatophagoides farinae. The content of alpha-enolase of dermatophagoides farinae is reduced; the reproduction of mites is reduced; in addition, the Dermatophagoides farinae enolase and human enolase can form a cross antigen to cause autoimmune diseases of a human body, and the Dermatophagoides farinae alpha-enolase gene dsRNA can be used as an acaricide to reduce the autoimmune diseases of the human body caused by the Dermatophagoides farinae alpha-enolase.

The present invention provides a novel antibody fragment based antifungal conjugate selectively targeting Candida spp. comprising of at least one antimicrobial peptide at one end of the conjugate, more particularly, human Histatin-5; an antibody fragment at the other end of the conjugate, specific against Candida spp. enolase, a virulence factor protease and biofilm specific antigen of Candida spp.; at least one signal protease cleavage sequence susceptible to cleavage by virulent protease secreted by Candida spp., secreted aspartyl proteinase-1 (SAP1); and at least one flexible polypeptide linker. The signal protease cleavage sequence and the flexible polypeptide linker are in tandem with each other and placed in between the antimicrobial peptide and the antibody. The in vitro MIC-99 of the conjugate against Candida spp., is in the range of 0.2-0.3 μM, more specifically, 0.25 μM or 250 nM.

Provided herein are methods for treating an angiogenesis-related disease comprising administration to a subject in need thereof an effective amount of alpha-enolase (enolase-1, ENO-1) antagonist.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention discloses an application of a hyperbaric oxygen-induced sodium channel active marker in epilepsy susceptibility evaluation. Belongs to the technical field of biomedicine. In the application, a sodium channel active marker comprises peripheral blood sodium channel protein, peripheral blood phosphorylated sodium channel protein, neuron-specific enolase, S100B protein and epilepsy discharge frequency. The high-pressure oxygen induction condition is that the pressure is increased to 2.0 absolute atmospheric pressure within 15 min, then pure oxygen is absorbed for 1 h under the stable pressure condition, and finally the pressure is reduced to normal pressure at a constant speed within 15 min. The method has the advantages of being high in evaluation accuracy and small in harm to human bodies, and the problem that in the prior art, epilepsy susceptible high-risk groups cannot be screened is effectively solved.

The present disclosure relates to methods and materials for the production of resveratrol in yeasts (e.g., yeast of the Saccharomyces genus such as S. cerevisiae) by increasing expression of genes of the pentose phosphate or Shikimate pathway and others, such genes, for example, encoding acetyl-CoA synthase, transketolase, transaldolase, enolase, aromatic aminotransferase, prephenate dehydratase, ribose-5-phosphate isomerase, or a monocarboxylate permease.